Products for Research Use Only

RANKL-IN-1

CAT: 0804-HY-175703Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-175703Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
RANKL-IN-1 is a selective and orally active Receptor Activator of Nuclear Factor-κ B Ligand (RANKL) inhibitor with a KD value of 7.6 μM. RANKL-IN-1 exhibits inhibitory activity and selectivity against osteoclastogenesis with an IC50 value of 0.07 μM and SI of 82.57. RANKL-IN-1binds directly to RANKL and blocks the RANKL-induced activation of the NF-κB and MAPK pathways. RANKL-IN-1 can be used for the research of metabolic disease, such as osteoporosis[1].
UNSPSC
12352005
Target
ERK; JNK; MMP; NF-κB; p38 MAPK; RANKL/RANK ; Reactive Oxygen Species (ROS)
Related Pathways
Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; Stem Cell/Wnt
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Smiles
CC1=C(C2=CC3=NC=CN=C31)C=C[C@@]4(C2=CC[C@@]5([C@@]4(CC[C@@]6([C@H]5C[C@](C(N7CCC(CC7)N8CCNCC8)=O)(CC6)C)C)C)C)C
Molecular Formula
C40H55N5O
Molecular Weight
621.90
References & Citations
[1]Fu X, et al. Design, Synthesis, and Biological Evaluation of Heterocycle-Fused Celastrol Derivatives as Potent Antiosteoporosis Agents by Blocking RANKL-Induced Activation of the NF-κB and MAPK Signaling Pathways. J Med Chem. 2025 Aug 28;68 (16) :17678-17704.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
MMP-9